Lymphoma

Latest News


FDA approval: developing story

The Food and Drug Administration approved Polivy plus Rituxan, cyclophosphamide, doxorubicin and prednisone for patients with previously untreated diffuse large B-cell lymphoma — marking the first new regimen in nearly two decades for this patient population.

top FDA approvals of 2022

There were some monumental FDA approvals in the cancer space during 2022 — here’s a roundup of our most-read agency decisions of the year.